RxDoctor Payments DataLook up a doctor →

Ahmed Elsharkawi, MD

Nephrology · Brunswick, GANPI 1861456378

Payments from drug & device makers

$775,068in general payments, 2019–2025

Across 631 payments — averaging $1228.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$239K
  • AstraZeneca$194K
  • Amgen$133K
  • Vertex$103K
  • Bayer$89K
  • Alnylam Pharmaceuticals Inc.$10K
  • plus $7K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
CSL Behring50$238,779
AstraZeneca(2 entities)59$194,056
Amgen(2 entities)89$133,105
Vertex5$102,987
Bayer33$88,941
Alnylam Pharmaceuticals Inc.3$10,031
Mallinckrodt Hospital Products Inc.52$1,054
Vifor Pharma, Inc.23$571
Novo Nordisk38$489
Travere Therapeutics, Inc.37$480
ANI Pharmaceuticals, Inc.19$462
Otsuka America Pharmaceutical, Inc.18$397
Novartis18$361
AbbVie18$358
Fresenius USA Marketing, Inc.16$323
Lilly USA, LLC18$284
GSK14$267
OPKO Pharmaceuticals, LLC16$238
Mallinckrodt Enterprises LLC10$158
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$141
Abbott6$128
Aurinia Pharma U.S., Inc.7$127
Calliditas Therapeutics US Inc.7$124
Sanofi4$92
Takeda Pharmaceuticals U.S.A., Inc.4$69
Akebia Therapeutics Inc4$67
Boehringer Ingelheim3$62
Mannkind Corporation1$59
Dexcom, Inc.4$54
Sunovion Pharmaceuticals Inc.4$52
Eisai Inc.3$50
Ultragenyx Pharmaceutical Inc.3$44
Ascendis Pharma Endocrinology Inc2$44
Daiichi Sankyo Inc.2$40
Amarin Pharma, Inc.2$36
Pfizer2$35
Regeneron Healthcare Solutions, Inc.2$33
Genentech USA, Inc.1$32
Shire North American Group Inc2$32
Xeris Pharmaceuticals, Inc.2$32
Ardelyx, Inc.1$31
Scpharmaceuticals Inc.1$31
E.r. Squibb & Sons, L.L.C.2$27
Lundbeck LLC2$26
Boston Scientific1$26
Inspire Medical Systems, Inc.1$23
Insulet Corporation1$22
Ironwood Pharmaceuticals, Inc1$21
Johnson & Johnson1$18
Corcept Therapeutics1$18
Vivus LLC1$17
Hikma Pharmaceuticals USA1$16
Eyevance Pharmaceuticals LLC1$16
Esperion Therapeutics, Inc.1$15
Currax Pharmaceuticals LLC1$15
Kowa Pharmaceuticals America, Inc.1$14
Arbor Pharmaceuticals, Inc.1$13
Sanofi-aventis U.S. LLC1$13
Astellas Pharma US Inc1$12

How this compares

$775,068 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia →

Medicare billing

Part B allowed, 2024
$541,354
Medicare patients
799
Services billed
4,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Brunswick

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →